Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-955176, Placebo (Part 1), BMS-955176, Moxifloxacin, Placebo (Part 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 315 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Type 2 Diabetes
Interventions: Exercise program, Ascorbic Acid (Vitamin C); Behavioral · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 8,588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 318
States / cities: Andalusia, Alabama • Athens, Alabama • Birmingham, Alabama + 249 more

Conditions: Autism, Food Allergies
Interventions: NAET with acupressure and/or chiropractic procedures; Procedure
Lead sponsor: Nambudripad's Allergy Research Foundation; Other
Eligibility: 3 Years to 10 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Buena Park, California

Conditions: Down Syndrome
Interventions: Babble Boot Camp; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 0 Months to 12 Months
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Multiple Myeloma
Interventions: Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT); Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Taselisib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Interventions: AK006-IV, Placebo-IV, AK006-SC, Placebo-SC; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 16 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: BeCare Link LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Autism or Autistic Traits, Family Relations
Interventions: Transitioning Together (TT) / Juntos en la Transicion (JET), Usual autism transition care; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 14 Years to 21 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions: PF-06817024, Placebo for PF-06817024; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 20
States / cities: Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more

Conditions: Multiple Sclerosis
Interventions: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS), BIPAMS + Diet; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cognition Disorders, Multiple Sclerosis
Interventions: C105; Drug
Lead sponsor: Cognition Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Tuscon, Arizona • Lancaster, California + 26 more

Conditions: Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions: Intermittent self-catheterisation; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: West Orange, New Jersey • Philadelphia, Pennsylvania

Conditions: Anemia, Arthritis, Total Knee Arthroplasty, Total Hip Arthroplasty
Interventions: Conventional Oral TXA (Tranexamic Acid), Multi-Dose Oral TXA (Tranexamic Acid); Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Myelogenous Leukemia in Chronic Phase
Interventions: Nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 32
States / cities: Anaheim, California • Burbank, California • Concord, California + 27 more

Conditions: Multiple Myeloma
Interventions: bb21217; Biological
Lead sponsor: 2seventy bio; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: San Francisco, California • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Myopia
Interventions: galyfilcon A prototype lens, marketed galyfilcon A lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Cupertino, California • Huntington Beach, California • Los Angeles, California + 6 more

Conditions: Retinitis Pigmentosa, Retinal Dystrophy
Interventions: Observational; Other
Lead sponsor: Nanoscope Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 7
States / cities: Phoenix, Arizona • Beverly Hills, California • Miami, Florida + 4 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: ASP5094, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 4 more

Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions: Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more

Conditions: Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biospecimen Collection, Immune Checkpoint Inhibitor; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chemotherapy-induced Peripheral Neuropathy, Plasma Cell Myeloma
Interventions: VascuTherm5 vascular compression device; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)

A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects

Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes

Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)

Treatment of Autistic Children Using NAET Procedures

Proactive Speech and Language Intervention for Infants With Down Syndrome

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria

Validation of the BeCare Multiple Sclerosis Assessment App

Transitioning Together Boston

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Activity and Balanced Eating to Reduce Comorbidities and Symptoms of MS

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty

CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib

Study of bb21217 in Multiple Myeloma

Pilot Evaluation of a New Galyfilcon A Contact Lens Compared to a Marketed Galyfilcon A Contact Lens

Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma